Novartis And Quark Partner On Phase II siRNA Drug For Kidney Damage Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.